Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Estradiol valerate/dienogest - Bayer Schering Pharma

Drug Profile

Estradiol valerate/dienogest - Bayer Schering Pharma

Alternative Names: BAY 865027; Dienogest/estradiol valerate - Bayer Schering Pharma; DUB Qlaira; DUB-OC; E2/DNG - Bayer Schering Pharma; Natazia; Qlaira; SH T00658; SH T00658ID; SH T00658K; SH T00658L

Latest Information Update: 22 Sep 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals; Bayer HealthCare Pharmaceuticals Inc.
  • Class Estradiol congeners; Estrenes; Hormonal replacements; Oral contraceptives; Small molecules; Steroids; Testosterone congeners
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Metrorrhagia; Pregnancy

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Jun 2015 Bayer completes a phase III trial in Metrorrhagia in China, Philippines, Russia, Singapore, Taiwan and Thailand (NCT01638923)
  • 02 Mar 2015 Estradiol valerate/dienogest is still in a phase III trial for Metrorrhagia in China, Philippines, Russia, Singapore, Taiwan and Thailand (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top